Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in MEN Patients | Research

The takeaway

PRRT (peptide receptor radionuclide therapy using radiolabeled somatostatin analogs) showed safety and efficacy in treating neuroendocrine tumors in patients with multiple endocrine neoplasia syndromes.

Peptide-targeted radiation
Somatostatin analog peptides deliver radiation directly to neuroendocrine tumors in MEN patients, with demonstrated safety and efficacy

What the researchers found

PRRT with radiolabeled somatostatin analogs was safe and effective for neuroendocrine tumors in MEN patients, extending this peptide-targeted therapy to a complex and underserved population.

Why it matters

MEN patients have complex multi-tumor disease and limited treatment options. Demonstrating PRRT safety and efficacy in this population expands access to peptide-targeted radiation therapy for patients who need it most.

The numbers in context

Up to 4 cycles of ¹⁷⁷Lu-DOTATATE (5.5-7.4 GBq per cycle) administered every 8-12 weeks.

How the study worked

Clinical study of PRRT safety and efficacy in MEN patients with neuroendocrine tumors. Assessed tumor response, survival outcomes, and adverse events.

Who was studied

MEN syndrome patients with advanced, inoperable, or metastatic neuroendocrine tumors

What this study cannot tell us

MEN patients represent a small, heterogeneous population. Study size may be limited. Long-term outcomes in MEN patients need follow-up.

How to read the evidence

Moderate evidence: clinical study in a specific patient population extending known PRRT benefits to MEN patients.

When this study was published

Published in 2025. Extends PRRT evidence to multiple endocrine neoplasia syndromes.

The bigger picture

PRRT represents one of the most successful clinical applications of therapeutic peptides — using somatostatin analog peptides as targeted delivery vehicles for radiation. Expanding this to MEN patients demonstrates the versatility of peptide-targeted therapy in complex oncological settings.

Questions still open

Should PRRT be considered earlier in MEN patient treatment algorithms?
How do MEN patient PRRT outcomes compare to sporadic neuroendocrine tumor patients?
Can PRRT be combined with other targeted therapies for MEN tumors?

Common questions

What is PRRT?

Peptide receptor radionuclide therapy attaches a radioactive atom to a somatostatin analog peptide. When injected, the peptide seeks out and binds to somatostatin receptors on neuroendocrine tumors, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue.

Can MEN patients receive PRRT?

This study shows yes — PRRT was safe and effective in MEN patients with neuroendocrine tumors. While MEN patients were often excluded from earlier PRRT trials due to their complex multi-tumor disease, this study supports its use in this population.

Read the original research

Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.

Clinical nuclear medicine, 50(7), 605-611

View on PubMed ↗Publisher’s paper ↗

Citation

Aggarwal, Piyush; Satapathy, Swayamjeet; Kaur, Gurjeet; Sood, Ashwani; Bhadada, Sanjay Kumar; Walia, Rama; Gupta, Rajesh; Mittal, Bhagwant Rai. (2025). Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.. Clinical nuclear medicine, 50(7), 605-611. https://doi.org/10.1097/RLU.0000000000005891